fibrinolytic

简明释义

英[/ˌfaɪ.brɪ.nəˈlɪt.ɪk/]美[/ˌfaɪ.brɪ.nəˈlɪt.ɪk/]

adj. 溶解纤维蛋白的

英英释义

单词用法

同义词

反义词

例句

1.Conclusion it was suggested that the abnormal activities of fibrinolytic system is associated with insulin resistance in CHD.

结论冠心病患者的纤溶系统活性异常与胰岛素抵抗有关。

2.Plasminogen activator inhibitor-1 (PAI-1) is the main regulator of the fibrinolytic system.

血浆纤溶酶原激活物抑制剂(PAI) - 1是纤溶系统的主要调控因子。

3.Objective to evaluate the relationship of fibrinolytic activity with hematoma enlargement in spontaneous intracerebral hemorrhage (ICH).

目的探讨脑出血(ICH)继续出血与血液纤溶活性的关系。

4.Objective To explore the clinical significance of examine a series of hemostatic and fibrinolytic indexes in malignant blood disease.

目的检测恶性血液病病人的凝血和纤溶指标，探讨其在恶性血液病中的临床意义。

5.Objective To study the fibrinolytic abnormalities in acute leukemia (al).

目的探讨急性白血病(AL)患者纤溶系统的异常。

6.CONCLUSIONS Ultraviolet irradiation may activate fibrinolytic system and solve the thrombus near vascular anastomosis.

结论紫外线照射可激活纤溶系统，溶解血管吻合口局部血栓。

7.In cases of acute myocardial infarction, fibrinolytic 纤溶药 therapy can significantly reduce mortality rates.

在急性心肌梗死的情况下，fibrinolytic 纤溶药治疗可以显著降低死亡率。

8.The effectiveness of fibrinolytic 纤溶药 therapy varies depending on the type of stroke.

治疗的有效性取决于中风的类型，fibrinolytic 纤溶药治疗的效果各异。

9.The fibrinolytic 纤溶药 agent was administered within the first hour of symptom onset.

该fibrinolytic 纤溶药剂在症状出现后的第一小时内给予。

10.The doctor prescribed a fibrinolytic 纤溶药 to help dissolve the blood clot in the patient's leg.

医生开了一种fibrinolytic 纤溶药来帮助溶解病人腿部的血栓。

11.Patients receiving fibrinolytic 纤溶药 treatment must be monitored for potential bleeding complications.

接受fibrinolytic 纤溶药治疗的患者必须监测潜在的出血并发症。

作文

The human body is an intricate system that relies on various biochemical processes to maintain health and functionality. One of the crucial processes involved in maintaining the balance of blood flow and preventing excessive clotting is known as fibrinolysis. This process is primarily facilitated by agents referred to as fibrinolytic agents. These agents play a vital role in breaking down fibrin, a protein that forms the structural basis of blood clots. Understanding the function and importance of fibrinolytic agents can provide insights into their therapeutic applications in medicine.Fibrinolysis is the process by which the body naturally dissolves blood clots. When a blood vessel is injured, the body initiates a cascade of events to form a clot, which is essential for stopping bleeding. However, once the vessel is healed, it is equally important to remove the clot to restore normal blood flow. This is where fibrinolytic agents come into play. They help to degrade fibrin and other components of the clot, thereby allowing the blood to flow freely again.There are several types of fibrinolytic agents, including tissue plasminogen activator (tPA), streptokinase, and urokinase. Each of these agents works by converting plasminogen, a precursor molecule, into plasmin, the active enzyme responsible for breaking down fibrin. The use of fibrinolytic therapy has become increasingly common in clinical settings, particularly in the treatment of conditions such as myocardial infarction (heart attack) and pulmonary embolism. In these situations, timely administration of fibrinolytic agents can be life-saving, as they rapidly dissolve clots that obstruct blood vessels.Despite their benefits, the use of fibrinolytic agents is not without risks. One of the primary concerns is the potential for bleeding complications. Since these agents promote the breakdown of clots, there is a risk of causing excessive bleeding, particularly in patients who have underlying bleeding disorders or who are taking anticoagulant medications. Therefore, careful patient selection and monitoring are essential when using fibrinolytic therapy.Moreover, researchers continue to explore new fibrinolytic agents and strategies to enhance their efficacy while minimizing risks. Advances in biotechnology have led to the development of modified versions of existing agents that may offer improved safety profiles. Additionally, combining fibrinolytic therapy with other treatments, such as antiplatelet medications, may enhance overall outcomes in patients with acute thrombotic events.In conclusion, fibrinolytic agents are essential tools in modern medicine, particularly in the management of thromboembolic disorders. Their ability to dissolve blood clots quickly can save lives, but their use must be balanced with the potential risks of bleeding. Ongoing research and innovation in this field will undoubtedly lead to safer and more effective therapeutic options for patients in the future. Understanding the role of fibrinolytic agents is crucial for both healthcare professionals and patients alike, as it underscores the delicate balance the body maintains in its hemostatic processes.

人体是一个复杂的系统，依赖各种生化过程来维持健康和功能。其中一个涉及维持血流平衡和防止过度凝血的关键过程被称为纤溶作用。这个过程主要由被称为纤溶酶的药物促进。这些药物在分解纤维蛋白方面发挥着至关重要的作用，纤维蛋白是一种形成血栓结构基础的蛋白质。理解纤溶酶的功能和重要性可以提供其在医学中治疗应用的见解。纤溶作用是身体自然溶解血栓的过程。当血管受伤时，身体会启动一系列事件以形成血栓，这对于止血至关重要。然而，一旦血管愈合，去除血栓同样重要，以恢复正常的血流。这就是纤溶酶发挥作用的地方。它们有助于降解纤维蛋白和血栓的其他成分，从而使血液再次自由流动。有几种类型的纤溶酶，包括组织型纤溶酶原激活剂（tPA）、链激酶和尿激酶。这些药物通过将纤溶酶原（前体分子）转化为纤溶酶（负责分解纤维蛋白的活性酶）来工作。在临床环境中，使用纤溶酶治疗变得越来越普遍，特别是在心肌梗塞和肺栓塞等疾病的治疗中。在这些情况下，及时给予纤溶酶药物可能是挽救生命的，因为它们迅速溶解阻塞血管的血栓。尽管有其好处，但使用纤溶酶药物并非没有风险。主要的担忧之一是出血并发症的潜在风险。由于这些药物促进血栓的降解，因此存在引起过度出血的风险，尤其是在有基础出血障碍或正在服用抗凝药物的患者中。因此，在使用纤溶酶治疗时，仔细选择患者和监测至关重要。此外，研究人员继续探索新的纤溶酶药物和增强其疗效的策略，同时最小化风险。生物技术的进步导致了现有药物的改良版本的发展，这可能提供更好的安全性。此外，将纤溶酶治疗与其他治疗（如抗血小板药物）结合使用，可能增强急性血栓事件患者的整体效果。总之，纤溶酶药物是现代医学中的重要工具，特别是在血栓栓塞性疾病的管理中。它们快速溶解血栓的能力可以挽救生命，但其使用必须与出血的潜在风险相平衡。该领域的持续研究和创新无疑将导致未来为患者提供更安全、更有效的治疗选择。理解纤溶酶药物的作用对于医疗专业人员和患者来说都是至关重要的，因为它强调了身体在止血过程中保持的微妙平衡。